CS
DNTH icon

Credit Suisse’s Dianthus Therapeutics DNTH Stock Holding History

Credit Suisse’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,331
Closed -$113K – 3147
2023
Q2 		$113K Sell
9,331
-2,763
-23% -$31.4K ﹤0.01% 3130
2023
Q1 		$154K Hold
12,094
– – ﹤0.01% 3162
2022
Q4 		$76.4K Hold
12,094
– – ﹤0.01% 3365
2022
Q3 		$273K Sell
12,094
-1
-0% -$27 ﹤0.01% 3120
2022
Q2 		$232K Sell
12,095
-48
-0.4% -$1.19K ﹤0.01% 3278
2022
Q1 		$563K Sell
12,143
-8
-0.1% -$437 ﹤0.01% 2903
2021
Q4 		$861K Buy
12,151
+2,378
+24% +$239K ﹤0.01% 3429
2021
Q3 		$1.14M Buy
9,773
+7,159
+274% +$834K ﹤0.01% 3238
2021
Q2 		$409K Sell
2,614
-81
-3% -$14.9K ﹤0.01% 3952
2021
Q1 		$510K Sell
2,695
-932
-26% -$157K ﹤0.01% 3753
2020
Q4 		$455K Buy
3,627
+191
+6% +$21.7K ﹤0.01% 3844
2020
Q3 		$374K Buy
3,436
+2,168
+171% +$257K ﹤0.01% 3534
2020
Q2 		$152K Buy
1,268
+140
+12% +$19.7K ﹤0.01% 3791
2020
Q1 		$113K Buy
+1,128
New +$209K ﹤0.01% 3795

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Credit Suisse's DNTH Position: Q3 2023 in Review

Credit Suisse sold out of Dianthus Therapeutics (DNTH) in Q3 2023, closing a stake of 9,331 shares — an estimated $113K sold.

Credit Suisse first reported a position in DNTH in Q1 2020 and held it in 14 quarters. The position peaked at $1.14M in Q3 2021. 30 funds tracked by Wall St. Rank hold DNTH as of Q3 2023.

  • Credit Suisse reported no remaining Dianthus Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Credit Suisse sold 9,331 Dianthus Therapeutics shares in Q3 2023, an estimated $113K.
  • Credit Suisse first reported a position in Dianthus Therapeutics in Q1 2020 and held it in 14 quarters.
  • Credit Suisse's Dianthus Therapeutics position peaked at $1.14M in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2023.

Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.